CORT Corcept Therapeutics
WatchlistCorcept Therapeutics News
Corcept Therapeutics Insider Sold Shares Worth $204,063, According to a Recent SEC Filing
Gary Charles Robb, Chief Business Officer, on December 04, 2023, sold 7,593 shares in Corcept Therapeutics (CORT) for $204,063. Following the Form 4 filing with the SEC, Robb has control over a total
Insider Sell: Joseph Lyon of Corcept Therapeutics Inc (CORT) Sells 5,000 Shares
Corcept Therapeutics(CORT.US) Director Sells US$56,034 in Common Stocks
$Corcept Therapeutics(CORT.US)$ Director Swisher Daniel N JR sold 2,200 shares of Common Stocks on Dec 1, 2023 at an average price of $25.47 for a total value of $56,034.Source: Announcement What is s
Corcept Therapeutics(CORT.US) Officer Sells US$130K in Common Stocks
$Corcept Therapeutics(CORT.US)$ Officer Lyon Joseph Douglas sold 5,000 shares of Common Stocks on Dec 1, 4, 2023 at an average price of $26 for a total value of $130K.Source: Announcement What is stat
Corcept Therapeutics(CORT.US) Officer Sells US$639.05K in Common Stocks
$Corcept Therapeutics(CORT.US)$ Officer Maduck Sean sold 25,000 shares of Common Stocks on Dec 1, 2023 at an average price of $25.5619 for a total value of $639.05K.Source: Announcement What is statem
Possible Bearish Signals With Corcept Therapeutics Insiders Disposing Stock
The fact that multiple Corcept Therapeutics Incorporated (NASDAQ:CORT) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. Knowin
Corcept Therapeutics (CORT) Gets a Buy From Piper Sandler
Are Investors Undervaluing Corcept Therapeutics Incorporated (NASDAQ:CORT) By 37%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Corcept Therapeutics fair value estimate is US$41.23 Current share price of US$25.91 suggests Corcept Therapeutics is potentially 37% underva
Truist Upgrades Corcept to Buy, Cites Market Potential for Relacorilant
Truist Securities Upgrades Corcept Therapeutics to Buy, Raises Price Target to $38
Truist Securities analyst Joon Lee upgrades Corcept Therapeutics (NASDAQ:CORT) from Hold to Buy and raises the price target from $29 to $38.
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Intellia Therapeutics (NTLA) and Corcept Therapeutics (CORT)
Corcept Therapeutics(CORT.US) Officer Sells US$140.52K in Common Stocks
$Corcept Therapeutics(CORT.US)$ Officer Lyon Joseph Douglas sold 5,000 shares of Common Stocks on Nov 1, 2, 2023 at an average price of $28.104 for a total value of $140.52K.Source: Announcement What
Corcept Therapeutics(CORT.US) Officer Sells US$702.6K in Common Stocks
$Corcept Therapeutics(CORT.US)$ Officer Maduck Sean sold 25,000 shares of Common Stocks on Nov 1, 2, 2023 at an average price of $28.104 for a total value of $702.6K.Source: Announcement What is state
Corcept Therapeutics(CORT.US) Director Sells US$61,512 in Common Stocks
$Corcept Therapeutics(CORT.US)$ Director Swisher Daniel N JR sold 2,200 shares of Common Stocks on Nov 1, 2023 at an average price of $27.96 for a total value of $61,512.Source: Announcement What is s
Clorox To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page Needham cut
HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $34
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $32 to $34.
Corcept Therapeutics Increases FY23 Revenue From $455M-$470M To $470M-$480M Vs $465.62M Est.
Corcept Therapeutics Increases FY23 Revenue From $455M-$470M To $470M-$480M Vs $465.62M Est.
Corcept Therapeutics GAAP EPS of $0.28 Beats by $0.06, Revenue of $123.6M Beats by $3.88M
Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Posts Q3 EPS $0.28, Vs. Street Est of $0.23
04:17 PM EDT, 11/01/2023 (MT Newswires) -- Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Posts Q3 EPS $0.28, vs. Street Est of $0.23
Corcept Appoints Monica Tellado as President, Emerging Markets
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine,